Company Profile

Expression Genetics Inc (AKA: EGEN)
Profile last edited on: 5/23/17      CAGE: 41QT6      UEI:

Business Identifier: DNA/RNAi Delivery and Therapeutics
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

601 Genome Way
Huntsville, AL 35806
   (256) 512-0077
Location: Single
Congr. District: 05
County: Madison

Public Profile

In June 2014 Celsion Corporation (Celsion) (NASDAQ: CLSN) - an oncology drug development company - acquired EGEN, Inc. Expression Genetics, Inc. (EGEN), had been privately held biopharmaceutical company specializing in nucleic acid (DNA and RNAi) delivery and therapeutics aimed at specific disease targets. The Company had been focused on developing therapeutics for the treatment of human diseases including cancer and cardiovascular disease. EGEN has research pipeline products aimed at treatment of various cancers and cardiovascular disease involving siRNA, shRNA, tumor antigens, and angiogenic genes. EGEN has collaborations with outside investigators, biotech organizations, and universities on various projects in these areas.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2007 1 NIH $163,713
Project Title: Novel Combination Treatments For Brain Tumors

Key People / Management

  Khursheed Anwer -- President and Chief Scientific Officer

  Jason G Fewell

  Danny H Lewis

  James A McCarthy -- Senior Vice President, Corporate Development